Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Completed 11Terminated 3Active not recruiting 3Unknown 1Suspended 1Recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 2Gynecologic 1

Conditions

Melanoma 2Neoplasms 1Fallopian Tube Neoplasms 1

Interventions

Cyclophosphamide 389Carboplatin 343Gemcitabine 331pembrolizumab 328Cisplatin 327Paclitaxel 294Radiotherapy 291Docetaxel 285Bevacizumab 249Rituximab 233Capecitabine 221Nivolumab 218Dexamethasone 205Fluorouracil 189fludarabine 177Oxaliplatin 177Pemetrexed 153Doxorubicin 152Irinotecan 147Etoposide 144Leucovorin 143Cytarabine 133Bortezomib 129fludarabine phosphate 128Cetuximab 126Lenalidomide 125Filgrastim 119Erlotinib Hydrochloride 119Temozolomide 111Radiosurgery 110

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Interventional × Monatide (IMS 3015) × Clear all
NCT01810016 2022-10-12

NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma

Ludwig Institute for Cancer Research

Phase 1 Terminated
8 enrolled 16 charts
Dermatologic

Melanoma, Neoplasms

NCT01308294 2020-06-11

LAG-3/IMP321

Centre Hospitalier Universitaire Vaudois

Phase 1/2 Terminated
16 enrolled 12 charts
Dermatologic

Melanoma

NCT02452775 2020-04-24

Autologous OC-L Vaccine and Ovarian Cancer

Abramson Cancer Center at Penn Medicine

Phase 1 Terminated
3 enrolled
Gynecologic

Fallopian Tube Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡